Zacks Gives Neutral Rating to Hanger Orthopedic (HGR)
Several other analysts have also recently commented on the stock. Analysts at Barclays Capital (NYSE: BCS) raised their price target on shares of Hanger Orthopedic from $22.00 to $28.00 in a research note to investors on Thursday, May 3rd. They now have an “overweight” rating on the stock. Analysts at Jefferies Group (NYSE: JEF) raised their price target on shares of Hanger Orthopedic to $27.00 in a research note to investors on Thursday, May 3rd.
Hanger Orthopedic opened at 23.81 on Tuesday. Hanger Orthopedic has a 52-week low of $14.57 and a 52-week high of $27.73. The company has a market cap of $809.0 million and a price-to-earnings ratio of 14.46.
Hanger Orthopedic last posted its quarterly earnings results on Wednesday, May 2nd. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.02. The company’s revenue for the quarter was up 8.8% on a year-over-year basis. Analysts expect that Hanger Orthopedic will post $0.49 EPS next quarter.
Hanger Orthopedic Group, Inc. owns and operates orthotic and prosthetic (O&P) patient-care centers (patient -care centers) in the United States.